Avigen, Inc. (NASDAQ: AVGN)

Avigen, Inc. (NASDAQ: AVGN), a biopharmaceutical company, engages in the development and commercialization of small molecule therapeutics designed to treat serious neurological disorders, including neuropathic pain and opioid addiction and withdrawal. The company’s strategic aim is to complete the requirements of clinical development for each of the candidates in its product pipeline, while seeking opportunities to expand its pipeline through internal research, acquisitions, and in-licensing. For further information, visit the Company’s web site at www.avigen.com.